Hua Medicine announced its updated product pipeline for dorzagliatin which is set forth below. As its two Phase 3 registration trials in China remain on track, and with over 600 patients having already completed the 24-week mark (for both trials together), the Company's preparation work for additional trials and studies to support its impending commercialization of dorzagliatin in China, and expansion of its future label continues in earnest. Working with leading key opinion leaders in both China and the United States, the Company will begin preparations and initiation of these studies now and through 2020. The Company expects to initiate its head to head comparison trial (HMM0303) with both sulfonylurea (glimepiride) and the global blockbuster, DPP-4 inhibitor (sitagliptin) in the second half of 2019. Dr. Li Xiaoying, Vice President of the Chinese Diabetes Society and Director of Endocrinology at the Zhongshan Hospital will be leading this trial. Shanghai Municipal Science & Technology Commission has provided a government grant subsidy in support of this important trial. For similar reasons, the Company is also beginning preparatory work for initiation of its head to head comparison trial (HMM0304) between dorzagliatin and -glucosidase inhibitor. The Company believes the Type 2 diabetes (`T2D") drug-naïve population in China provides a huge market opportunity due to the relatively low rate of diagnosis in China (estimated at only 47.7% in 2017 by Frost & Sullivan), and coupled with the government's explicit announcement to invest in areas outside of Tier 3 cities to increase that rate. The Company has observed, though, that many such Chinese T2D drug-naïve patients have already advanced to a rather late stage of T2D (as measured by their diagnosed HbA1c levels) when finally diagnosed. It is this specific population that the Company believes its combination with insulin could provide a very strong therapy regimen as first-line therapy, and the Company initiate this trial (HMM1202) in 2020. Within the next 12 months, the Company expects to announce top-line 24-week data for both of its Phase III trials in China, and also the results of its two Phase I combination drug-drug interaction trials in the United States. As of May 31, 2019, the Company has enrolled 630 patients into its combination with metformin Phase III trial (HMM0302) in China.